Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
Date:2/16/2010

span> for the third quarter of 2009 and $3.6 million for the fourth quarter of 2008.  For the full year of 2009, total expenses were $40.5 million, compared to $52.8 million for 2008.  Total 2009 R&D expenses were $13.9 million, compared to $23.9 million during 2008.

As of December 31, 2009, Vanda's cash, cash equivalents, and marketable securities totaled approximately $205.3 million.  As of December 31, 2009, a total of approximately 27.6 million shares of Vanda common stock were outstanding.  Net loss per common share for the fourth quarter of 2009 was $0.34, compared to $0.28 for the third quarter of 2009 and $0.28 for the fourth quarter of 2008. For the full year of 2009, net loss per common share was $1.33, compared to $1.92 for the full year of 2008.  

OPERATIONAL HIGHLIGHTS

During the fourth quarter of 2009, Vanda focused its efforts on the successful transition to Novartis of commercial, regulatory and manufacturing documents, materials and supplies relating to Fanapt™.  On January 11, 2010, Vanda announced that Novartis Pharmaceuticals Corporation had launched Fanapt™ in the U.S.  Vanda has explored, and continues to evaluate, the regulatory path and commercial opportunity for Fanapt™ outside of the U.S. and Canada.

Vanda also continued the clinical, regulatory and commercial evaluation of tasimelteon, its selective melatonin receptor agonist, during the fourth quarter of 2009.  Compoun
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
8. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014  FlexTech Alliance today issued a dual-focused ... demonstrators (demos) and a functional electronic print leaflet.  ... due on October 22, 2014 and full proposals ... selected are provided by the US Army Research ... by the proposing organization. Photo - ...
(Date:9/15/2014)... of fibers made of carbon nanotubes is neat, but Rice ... single-walled carbon nanotubes in new fibers created at Rice line ... designed by chemist Angel Mart and his colleagues. , The ... this month in the journal ACS Nano , is ... into a fiber. , Left to their own devices, carbon ...
(Date:9/15/2014)... 15, 2014 Zymo Research Corp., has announced ... for safe ambient temperature storage and transport of ... infectivity of agents in such samples is completely ... of the viral nucleic acids for subsequent analyses.  ... epidemic in West Africa ...
(Date:9/15/2014)... 2014 The chemistry, taste, and health effects of ... article published by the nonprofit American Botanical Council (ABC). Recent ... and its effects on the phytochemical compounds in tea ( ... by Dr. Ahmed in the Yunnan ... implications for the future of medicinal botanicals. Dr. Ahmed,s ...
Breaking Biology Technology:FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4
... N.J., Jan. 7 Par Pharmaceutical Companies, Inc. (NYSE: ... Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at ... The audio-only live webcast will be accessible through the J.P. ... the Par website at www.parpharm.com . A replay ...
... Technology Index Shows Stronger Performance in Turbulent EconomyOAKBROOK TERRACE, ... trade association representing all segments of the high-tech industry, ... Index (Nasdaq: ILTI ) outperformed the Dow ... Index(R) (COMP) since its inception in 2008.On May 19, ...
... and Efficient Cold Chain VisibilityBEVERLY, Mass., Jan. 7 ... in cold-chain visibility solutions, has launched the TempTale(R)4USB ... latest model of the industry-leading TempTale4 product line ... without proprietary software or readers. Sensitech is a ...
Cached Biology Technology:NASDAQ OMX AeA Illinois Tech Index Outperforms Market 2NASDAQ OMX AeA Illinois Tech Index Outperforms Market 3Introducing Sensitech's TempTale(R)4USB Temperature Monitor 2Introducing Sensitech's TempTale(R)4USB Temperature Monitor 3
(Date:9/15/2014)... The creation of the Vuoksi River and the subsequent ... approximately 6,000 years ago revealed thousands of square kilometres ... research project organised by University of Helsinki researchers has ... has played in the interaction between nature and humans. ... the area underwent significant changes and gave rise to ...
(Date:9/15/2014)... Schizophrenia is generally considered to be a disorder ... both genetic and environmental, with other neurodevelopmental disorders such ... for brain development is determined by the combined effects ... range of environmental factors. , However, longitudinal brain imaging ... in order to map the disturbances in brain structures ...
(Date:9/15/2014)... , , , , , , , ... , , , , , , ... shows that schizophrenia isn,t a single disease but a group of eight genetically distinct disorders, each with its own set of symptoms. The finding could be ... , , , , , ... , , , , ...
Breaking Biology News(10 mins):The creation of the Vuoksi River preceded a significant cultural shift 2Brain Development in Schizophrenia Strays from the Normal Path 2Schizophrenia not a single disease but multiple genetically distinct disorders 2Schizophrenia not a single disease but multiple genetically distinct disorders 3Schizophrenia not a single disease but multiple genetically distinct disorders 4Schizophrenia not a single disease but multiple genetically distinct disorders 5
... to tackle the human impact on biodiversity require ... working with common goals and frameworks. This emerged ... Science Foundation (ESF), which moved towards establishing an ... biodiversity analysis on the back of existing initiatives. ...
... dating back to the journals of Henry David Thoreau, scientists ... Walden Pond have borne the effects of climate change in ... by global warming have included beloved species like lilies, orchids, ... in the Proceedings of the National Academy of Sciences ...
... release is available in French . ... $100,000 grant from the Gates Foundation to help establish ... "People are always asking why the pharmaceutical ... the poor, like parasitic infections," said Dr. Timothy Geary, ...
Cached Biology News:European biodiversity and ecosystem scientists merge and gear up for long-term research 2Effects of climate change vary greatly across plant families 2Boost from McGill, Gates Foundation helps Africans control pharma research 2
...
... is essential for hunting and analyzing ... such as EST sequencing projects, microarrays, ... kit is developed for normalization of ... intended for directional cloning. While most ...
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
Biology Products: